Previous close | 29.33 |
Open | 29.33 |
Bid | 7.30 |
Ask | 13.30 |
Strike | 600.00 |
Expiry date | 2024-12-20 |
Day's range | 29.33 - 29.33 |
Contract range | N/A |
Volume | |
Open interest | 40 |
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the Catalyst® Pancreatic Lipase Test, a single-slide solution for canine and feline patients suspected of pancreatitis. With the innovative load-and-go workflow of the Catalyst analyzers, the test can run effortlessly alongside chemistry profiles, leading to a faster path to diagnosis and enhanced patient outcomes. The Catalyst Pancreatic Lipase Test will be available in the U.S. and Ca
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IDEXX Laboratories (NASDAQ:IDXX) has had a rough three months with its share price down 10%. But if you pay close...